Theravance Biopharma, INC

Theravance Biopharma, Inc. announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right (CVR) for future ampreloxetine proceeds.

Theravance Biopharma shareholders re-elected all director nominees and ratified the appointment of Ernst & Young LLP.

Theravance Biopharma reported Q1 2026 financial results, highlighting YUPELRI revenue growth, successful cost reduction initiatives, and an ongoing strategic review.

Theravance Biopharma and Mylan have settled patent litigation with Mankind Pharma, allowing generic YUPELRI launch in the U.S. from April 23, 2039.

Theravance Biopharma, Inc. reported strong fourth-quarter and full-year 2025 financial results, driven by YUPELRI and TRELEGY sales milestones, while announcing an organizational restructuring following negative ampreloxetine study results.

Theravance Biopharma announced an organizational restructuring and accelerated strategic review following the failure of its Phase 3 CYPRESS study for ampreloxetine.

Theravance Biopharma announced first-quarter 2026 financial results, reporting a net loss of $4.9 million, and confirmed the wind-down of its ampreloxetine program following unsuccessful Phase 3 trial results.

Theravance Biopharma reported a significant net income for the nine months ended September 30, 2025, driven by a $75.1 million gain from the sale of its remaining TRELEGY royalties to GSK, while advancing its ampreloxetine Phase 3 study.

Theravance Biopharma reported significant net income and cash flow for Q2 2025, driven by a $225 million sale of TRELEGY royalties to GSK and continued growth in YUPELRI sales.

Theravance Biopharma announces its Q1 2025 financial results, highlighting revenue growth from YUPELRI and advancements in the ampreloxetine clinical program.

Theravance Biopharma's Q3 2024 results show a net loss of $12.7 million, but YUPELRI sales hit a record high, driven by increased demand and market share.

Theravance Biopharma's second quarter 2024 results show stable YUPELRI sales and continued progress in the development of ampreloxetine.

Theravance Biopharma announced the wind-down of its ampreloxetine program following Phase 3 study failure, accelerating a strategic review while focusing on YUPELRI's continued sales growth and cost-cutting restructuring.

Theravance Biopharma's 2024 10-K filing highlights YUPELRI's net sales growth, continued progress in the Ampreloxetine Phase 3 clinical study, and a strategic review to unlock shareholder value.

Theravance Biopharma's 2023 annual report showcases YUPELRI's sales growth and the advancement of ampreloxetine into a new Phase 3 clinical study.

Eli Samaha, a Director and 10% owner of Theravance Biopharma, Inc., reported significant purchases of company stock between June 29 and July 1, 2026.

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, sold 13,314 ordinary shares via a 10b5-1 plan.

Theravance Biopharma director Laurie Smaldone Alsup was granted 6,009 ordinary shares and 13,398 stock options as part of annual compensation.

Director Susannah Gray has been granted 6,009 ordinary shares and 13,398 stock options as part of her compensation package.

Director Dean J. Mitchell has been granted 6,009 ordinary shares and 13,398 stock options as part of his compensation package.

Director Donal O'Connor was granted 6,009 ordinary shares and 13,398 stock options as part of his annual compensation package.

Theravance Biopharma announces its 2026 Annual General Meeting to be held on June 12, 2026, in Dublin, Ireland.

Theravance Biopharma will hold its 2025 Annual General Meeting on May 19, 2025, in Dublin, Ireland, to vote on director elections, auditor ratification, and executive compensation.

Theravance Biopharma will hold its 2024 Annual General Meeting on May 8, 2024, in Dublin, Ireland, to vote on director elections, auditor ratification, and executive compensation.

Weiss Asset Management LP and its affiliates have increased their beneficial ownership in Theravance Biopharma, Inc. to 14.5% of outstanding shares.

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 6.5% beneficial ownership stake in Theravance Biopharma, Inc. as of March 31, 2025.

Newtyn Management, LLC and its affiliates have disclosed a combined 9.7% beneficial ownership stake in Theravance Biopharma, Inc., as of December 31, 2024.